Blinding and expectancy confounds in psychedelic randomized controlled trials

  title={Blinding and expectancy confounds in psychedelic randomized controlled trials},
  author={Suresh D. Muthukumaraswamy and Anna Forsyth and Thomas Lumley},
  journal={Expert Review of Clinical Pharmacology},
  pages={1133 - 1152}
ABSTRACT Introduction: There is increasing interest in the potential for psychedelic drugs such as psilocybin, LSD and ketamine to treat several mental health disorders, with a growing number of randomized controlled trials (RCTs) being conducted to investigate the therapeutic effectiveness of psychedelics. Areas covered: We review previous literature on expectancy effects and blinding in the context of psychedelic RCTs – literature which strongly suggest that psychedelic RCTs might be… 
Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials
  • E. Schenberg
  • Psychology
    Expert review of clinical pharmacology
  • 2021
An in-depth and carefully argued overview of unblinding (also called de-blinding, unmasking or de-masking) including promising alternatives and careful procedures to improve research practices is presented, but it is dubious if the suggested practices will benefit patients.
Great Expectations: recommendations for improving the methodological rigor of psychedelic clinical trials.
RATIONALE Psychedelic research continues to garner significant public and scientific interest with a growing number of clinical studies examining a wide range of conditions and disorders. However,
A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
Methylenedioxymethamphetamine and psilocybin may show promise in highly selected populations when administered in closely supervised settings and with intensive support, and both agents were well tolerated in supervised trials.
Psychedelic resting-state neuroimaging: a review and perspective on balancing replication and novel analyses
The review of the existing literature suggests that the psychedelic resting-state brain imaging field is at a crossroads at which it must also consider the critical importance of consistency and replicability to effectively converge on stable representations of the neural effects of psychedelics.
The challenges ahead for psychedelic 'medicine'.
With the extensive public, commercial and scientific interest from what has been widely termed the psychedelic renaissance, it is important that the scientific practices and results obtained from its
Exploring the Credibility of Psilocybin-assisted Therapy and Cognitive-behavioral Therapy for Depression.
Examination of credibility ratings for CBT and PAT among individuals reporting depressive symptoms suggests that potential clients appear cautious about PAT, and researchers and clinicians must consider patients' beliefs about treatments as potential predictors of outcomes.


Placebo response in studies of major depression: variable, substantial, and growing.
The response to placebo in published trials of antidepressant medication for MDD is highly variable and often substantial and has increased significantly in recent years, as has the response to medication.
Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials.
Examination of patient expectancy and mixed-effects modeling revealed a significant week-by-group interaction, indicating that HAM-D scores for citalopram-treated participants declined at a faster rate in the open group compared with the placebo-controlled group.
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial
New evidence is brought new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression, in the first controlled trial to test a psychedelic substance in treatment-resistant depression.
Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial
An innovative multidisciplinary trial design that attempts to replicate and expand upon an earlier IBS OLP study by comparing, for the first time, OLP and DBP administration and explores genetic, psychological and experiential dimensions of OLP.
Active placebos versus antidepressants for depression.
The more conservative estimates from the present analysis found that differences between antidepressants and active placebos were small, which suggests that unblinding effects may inflate the efficacy of antidepressants in trials using inert placebos.
Psychedelics and the essential importance of context
This article highlights the pharmacological mechanisms of classic psychedelics that it is believed render their effects exceptionally sensitive to context, and develops an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits.
A randomized, prospective pilot study of patient expectancy and antidepressant outcome
Investigation of the relationships between clinical trial design, patient expectancy and the outcome of treatment with antidepressant medication found expectancy of improvement is affected by the probability of receiving active antidepressant medication and seems to influence antidepressant response.
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
A role for positive expectancy in predicting positive outcomes following psychedelic microdosing is highlighted and zealous inferences on its putative therapeutic value are cautions against.